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Abstract
The complement pathway has potential contributions to both white (WM) and grey matter
(GM) pathology in Multiple Sclerosis (MS). A quantitative assessment of complement
involvement is lacking. Here we describe the use of Tissue MicroArray (TMA) methodology
in conjunction with immunohistochemistry to investigate the localization of complement
pathway proteins in progressive MS cortical GM and subcortical WM. Antibodies targeting
complement proteins C1q, C3b, regulatory proteins C1 inhibitor (C1INH, complement
receptor 1 (CR1), clusterin, factor H (FH) and the C5a anaphylatoxin receptor (C5aR) were
utilised alongside standard markers of tissue pathology. All stained slides were digitised for
quantitative analysis. We found that numbers of cells immunolabelled for HLA-DR, GFAP,
C5aR, C1q and C3b were increased in WM lesions (WML) and GM lesions (GML)
compared to normal appearing WM (NAWM) and GM (NAGM), respectively. The
complement regulators C1INH, CR1, FH and clusterin were more abundant in WM lesions,
while the number of C1q1 neurons were increased and the number of C1INH1, clusterin1,
FH1 and CR11 neurons decreased in GM lesions. The number of complement component
positive cells (C1q, C3b) correlated with complement regulator expression in WM, but there
was no statistical association between complement activation and regulator expression in the
GM. We conclude that TMA methodology and quantitative analysis provides evidence of
complement dysregulation in MS GML, including an association of the numerical density of
C1q1 cells with tissue lesions. Our work conﬁrms that complement activation and
dysregulation occur in all cases of progressive MS and suggest that complement may provide
potential biomarkers of the disease.
INTRODUCTION
Pathology in multiple sclerosis (MS) is typiﬁed by white matter
lesions (WML), with characteristic inﬂammation, demyelination and
axonal loss (neuro-degeneration) (12, 18, 19, 25). Lesions are also
found in sub-cortical and cortical gray matter (GML), the latter being
a hallmark of the progressive phase (2, 4, 7, 14, 17, 22, 27, 29, 30).
There is an urgent need to uncover the components of the CNS
inﬂammatory response responsible for white and gray matter
pathology in progressive MS in order to inform therapies that slow
pathological and neurological decline. Among the implicated
components, there is growing pathological evidence for a signiﬁ-
cant contribution of complement (C), to neuro-inﬂammation in MS
(3, 5, 14, 16, 21, 23, 37).
Activation of C is a major driver of inﬂammation and pivotal to
innate and adaptive immune responses (24). Glia and neurons synthe-
size the classical pathway activation protein C1q, which binds numer-
ous potential ligands to initiate activation and generation of active
products, including the lytic membrane attack complex (MAC) and
the anaphylactic/chemotactic peptides C3a and C5a, chemo-
attractants for microglia expressing C5aR (8, 38). To limit self-injury,
neurons and glia express numerous C regulatory proteins (CReg)
including C1INH (C1 activation blockade), CR1, FH (alternative
pathway regulation) and clusterin (MAC assembly inhibition) (38).
We have previously reported detailed quantitative immunohisto-
chemical studies of complement proteins, activators and regulators,
showing increased C in plaque, peri-plaque and NAWM of
progressive MS compared with normal non-inﬂammatory control
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tissue (16) as well as in cortical gray matter lesions compared with
non-inﬂamed control tissue (37). Other studies in MS have focused
on determining cellular localization of individual C proteins (1, 5,
21). Here, to better understand the role of C activation and regula-
tion in progressive MS we have used tissue microarray (TMA)
methodology (36), quantitative pathology and statistical analysis.
This approach provides an unbiased, high throughput methodology
for analyzing tissue for localization of key C proteins and regula-
tors that can be correlated with measures of pathology in white and
gray matter MS lesions.
MATERIAL AND METHODS
Post-mortem cohort
Archived formalin ﬁxed parafﬁn embedded (FFPE) tissue blocks
obtained at autopsy from clinically and neuropathologically
validated progressive MS cases were provided by the Multiple
Sclerosis Tissue Bank Imperial College, London, under South East
Wales Research Ethics committee approval [10/WSE02/4]). Tissue
blocks were sampled from neocortex (WM and GM) and subcorti-
cal (WM and GM) sites.
Fourteen blocks from 13 cases of progressive MS were used:
mean age 51.1 years (38–79); clinical diagnosis: 9 secondary pro-
gressive MS (SPMS) (2 different FFPE blocks were used for case
MS230): 4 primary progressive MS (PPMS). Clinical information,
including age, sex, clinical onset and disease course are presented
in Table 1.
FFPE tissue blocks were obtained from cases of Alzheimer’s dis-
ease (n5 4; frontal and temporal lobe) and Herpes Simplex virus
encephalitis (n5 2; temporal lobe; supplied by Brains for Dementia
Research, Institute of Psychiatry Kings College, London, UK and
The Thomas Willis Brain Bank, Oxford University, Oxford, UK)
as positive staining controls for this study. All blocks were stained
with the same antibodies, in the same experimental run, as the
TMA cores (Table 2, Supporting Information Figures S1–S3).
FFPE tissue blocks were also obtained from control non-
inﬂammatory brain tissue cortex of three cases; CO38, CO40,
CO41 (see Table 2 for clinical details and tissue preservation
times), as described in the control cohort of Ingram and Loveless
(16). Tissue blocks were provided by the Multiple Sclerosis Tissue
Bank Imperial College, London.
Lesion classification
From each FFPE block, 4 micron sections were cut and stained
with hematoxylin & eosin (H&E) and Luxol fast blue (LFB).
Immunohistochemistry for lesion classiﬁcation was performed fol-
lowing deparafﬁnization and rehydration through a graded series of
ethanol : H2O mixtures. Antigen retrieval was performed using
0.05% citraconic anhydride (pH 7.4; Sigma) and all immunohisto-
chemistry (IHC) was performed using a DAKO autostainer, as pre-
viously described (16).
Lesion classiﬁcation was based on staining with the following
antibody panel: anti-HLA-DR, anti-Iba (ionized calcium binding
adaptor molecule 1, microglia marker), anti-MOG (myelin oligo-
dendrocyte glycoprotein), anti-CD20 (B lymphocyte marker) and
anti-CD3 (pan-T lymphocyte marker) (see Table 3).
Identification of demyelinated white matter
and gray matter lesions for TMA construction
Conventional histological staining with H&E, LFB, anti-HLA and
anti-MOG identiﬁed areas containing WML or GML. Applying cri-
teria described by Lassmann (18, 19), all WML selected were clas-
siﬁed as slowly expanding-chronic active plaques (residual
inﬂammation in center of demyelinated plaque with peripheral
boundary of activated microglia/macrophages containing myelin
degradation products). Cortical GML were classiﬁed as type I
(involving cortical GM and subcortical WM), type II (intracortical)
or type III (involving the subpial layers of the neocortex) cortical
GML based on location, according to Peterson (26). WML and
GML immunolabeling for B and T cell lymphocytes was restricted
to a perivascular and meningeal distribution in all sections (16).
Table 1. Chronic progressive MS case details. Mean age: 51.1 years, 10F:3M, Mean DTP: 18.2 hours, Mean DD: 25.3 years (n513 cases; 2
blocks taken from case MS230). All blocks contained cortical GM and subcortical WM. Abbreviations: DTP5death to preservation time;
DD5disease duration; SP5 secondary progressive; PP5 primary progressive.
Autopsy
number
Age Sex DTP
time (hrs)
MS disease
classification
Disease
duration (yrs)
Cause of death
MS106 39 F 18 PP 21 Bronchopneumonia
MS107 38 M 19 PP >16 Aspiration pneumonia, pulmonary edema
MS160 44 F 18 SP 15 Aspiration pneumonia, MS
MS197 51 F 10 SP 27 Bronchopneumonia, MS
MS203 53 F 17 SP 27 MS
MS225 79 F 23 SP 32 MS, diabetes mellitus, recurrent DVT
MS230 42 F 31 SP 20 MS
MS234 39 F 15 PP 15 Pulmonary embolism, pneumonia
MS249 59 F 8 SP 42 Chest infection, heart failure
MS255 45 M 24 SP 25 Bronchopneumonia, advanced MS
MS272 64 F 8 SP 37 Aspiration pneumonia Angiomatous meningioma
(Grade I, WHO 2007)
MS273 61 M 24 PP 31 UTI, septicemia, MS
MS377 50 F 22 SP 21 Aspiration pneumonia
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A single block per case, except for two blocks from two inde-
pendent lesions (case MS230), containing either chronic active
WML or type 1 cortical GML or both, of sufﬁcient size for tissue
core sampling, were selected following neuropathological analysis
for tissue microarray construction.
Tissue selection and construction of TMA
In all MS cases, three separate tissue cores (0.6 mm diameter;
0.28 mm2 area) were obtained from each lesion or normal tissue
area. Extraction of three tissue cores per area of interest has been
shown to increase concordance between quantiﬁcation obtained
with TMA cores and conventional wax sections (36). A Beecher
MTA-1 manual tissue arrayer (Estigen OU, Tartu, Estonia), with a
needle punch of diameter 0.6 mm, was inserted into the marked
areas on the donor blocks corresponding to the site of the lesion.
The donor tissue core was inserted into the recipient parafﬁn wax
block according to the array coordinates deﬁned in the pre-
determined template. Two TMA wax blocks were assembled; one
containing 120 tissue cores, the other, 110 cores taken from the 14
individual FFPE donor blocks, as described. In total, 224 tissue
cores were available for analysis (6 were not usable) with WM
(n5 51), WML (n5 82; including WM lesion center and WM
lesion edge), GM (n5 56), GML (n5 35; including GM lesion
center and GM lesion edge) (see Figure 1).
Immunohistochemistry
From each TMA block, 4 micron thick sections were cut. The fol-
lowing antibodies were used to detect C activation proteins and
CReg; mAb C3-30 (detects opsonins C3b and iC3b), anti-C1q,
anti-C1INH, anti-CR1, anti-clusterin, anti-C5aR. A panel of three
anti-FH antibodies and a mAb (MBC-125) recognizing FH-related
proteins 1, 2 and 5 (FHR 1,2,5) were included to differentiate
staining for FH and the FHRs. Sections from the TMAs, control
inﬂammatory brain tissue and control non-inﬂammatory brain
Table 2. Control cases. Clinical details of neuroinflammatory control cases; n56, mean age at death573.8 years, DTP550.3 hours, and non-
inflammatory control cases; n5 3, mean age at death5 75.0 years, DTP5 25.3 hours. Abbreviations: DTP5death to tissue preservation time.
Autopsy number Age Sex Death to tissue
preservation time (hrs)
Clinical
diagnosis
Neuropathological
findings
B5125–9 54 M 96 Encephalitis Herpes Simplex Encephalitis
B5046–15 42 M 72 Encephalitis Herpes Simplex Encephalitis
A173/05 81 F 17 Dementia Alzheimer’s Disease Braak V
A192/06 96 F 19 Dementia Alzheimer’s Disease Braak V
A303/09 80 M 60 Dementia Alzheimer’s Disease Braak III
A307/07 90 M 38 Dementia Alzheimer’s Disease Braak VI
CO38 85 M 27 Ischemic heart disease None
CO40 86 F 29 Acute cortical infarction Localized cortical infarction
CO41 54 M 20 Lung cancer None
Table 3. Antibodies used for immunohistochemistry. Citraconic anhydride (CA) buffer (pH 7.4) was used for antigen retrieval for all antibodies
except Iba-1 and C5aR, which used 0.01 M Sodium Citrate (SC) buffer (pH 6), biotin-tyramine and ABC staining method. Abbreviations:
mAb5monoclonal antibody; pAb5 polyclonal antibody; Conc5 concentration.
Antibody name Antigen/target Type,
species
Isotype Source Working conc
(mg/mL)
Antigen
retrieval method
HLA-DR Microglia mAb, mouse IgG1 DAKO #M0775 39.50 CA/Heat
Iba-1 Microglia pAb, rabbit IgG WAKO/Alpha Labs #019–19741 0.1 SC/Heat
GFAP Astrocytes mAb, mouse IgG1 DAKO #M0761 7.88 CA/Heat
MOG Y10 Myelin oligodendrocyte
glycoprotein
mAb, mouse IgG1 In-house 10 CA/Heat
Fibrinogen Fibrinogen pAb, rabbit IgG Abcam #Ab34269 1:75 diln of stock
solution
CA/Heat
C1q C1q pAb, rabbit IgG Alere #YYAO13602 36 CA/Heat
C3–30 C3b, iC3b mAb, mouse IgG1 In-house 3.21 CA/Heat
C1INH C1 inhibitor pAb, rabbit IgG In-house 42.3 CA/Heat
CR1 CR1 pAb, rabbit IgG In-house 6 CA/Heat
Affinity purified
anti-Clusterin
Clusterin pAb, rabbit IgG In-house 2.2 CA/Heat
Affinity purified
Poly FH
FH pAb, rabbit IgG In-house 2.8 CA/Heat
MBI-15 FH 10–15 SCRs mAb, mouse IgG1 In-house 14 CA/Heat
Ox-24 N-terminal of FH mAb, mouse IgG1 In-house 56 CA/Heat
MBC-125 FH-related proteins 1/2/5 mAb, mouse IgG1 In-house 57.2 CA/Heat
C5aR C5a Receptor/Anti-CD88 pAb, rabbit IgG BD Bioscience #550733 0.31 SC/Heat
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tissue, as detailed above, were processed and stained as described
(see Table 3 for antibody details and staining conditions, and Sup-
porting Information Figures S1–S3). Appropriate isotype-staining
with anti-IgG1 antibody using control and negative control tissue
were also included with each using methods described (16, 37).
Anti-ﬁbrinogen antibody was used to stain parafﬁn wax sections of
kidney, TMA and control non-inﬂamed cortex cases (see Support-
ing Information Figure S1).
In situ hybridization
In situ hybridization (ISH) was performed using a 50 ﬂuorescein
(FAM)-labeled 19mer antisense oligonucleotide containing nucleic
acid (LNA) and 20-O-methyl (20-O-Me)-RNA moieties in a 1:2 ratio.
Probes: antisense C1QA (NM_015991) FAM-TggTccTug
AugTuuCcu; scrambled C1QA FAM-GuuGuuCggTcuCuaGucT;
antisense C3 (NM_000064) FAM-TaaTccAccAauCauTucT; sense
C3 FAM-AgaAauGauUggUggAuuA (capitals indicate LNA and
lower case 20-O-Me RNA; Eurogentec, Southampton, UK). Follow-
ing de-waxing, rehydration and antigen retrieval, sections were pre-
hybridized in hybridization mix (37) before probe hybridization for
30 min in the same solution. Sections were then washed in decreasing
concentrations of saline-sodium citrate buffer, washed in PBS, incu-
bated with a peroxidase conjugated goat anti-FAM (Vector Labs) and
visualized with DAB. Sections were then blocked, incubated with
mouse anti-Human HuC/HuD neuronal protein overnight (clone
16A11, ThermoFisher Scientiﬁc), followed by a horse anti-mouse
biotin conjugated secondary, an avidin–biotin-AP tertiary and Vector
Blue AP substrate (all Vector Labs), Sections were dehydrated,
cleared in histoclear and coverslipped in VectaMount (Vector Labs).
Quantification of TMA immunolabeling
Individual immunolabeled TMA cores were digitally imaged (Zeiss
Mirax slide scanner and Pannoramic Viewer 3DHistech software).
Quantiﬁcation was performed manually using Image J software
Figure 1. Tissue characterization and TMA methodology. Panel A;
Luxol Fast Blue (LFB) staining and antibodies to MOG and HLA were
used to characterize whole sections from FFPE MS tissue blocks in
terms of demyelination and inflammation. All sampled white matter
lesions were classified as chronic active inflammatory lesions and
cortical gray matter lesions classified based on their location within
the neocortex. Three cores per region of interest, each of 0.6 mm
diameter (0.28 mm2 area) were extracted using a MicroArrayer from
the donor block and transferred to a recipient in a predetermined grid
location. Panel B; examples of whole TMAs stained with LFB, MOG
and HLA and cores from each area of interest; normal appearing
white matter (NAWM), white matter lesion edge and lesion center,
normal appearing gray matter (NAGM), gray matter lesion edge and
lesion center. Cores from lesion edge and lesion center were
combined and labeled white matter lesion (WML) and gray matter
lesion (GML) for analysis. Scale bars are shown. Abbreviations: LFB;
Luxol fast blue, MOG; myelin oligodendrocyte glycoprotein, FFPE;
formalin fixed paraffin embedded.
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4 Brain Pathology •• (2017) ••–••
VC 2017 International Society of Neuropathology
(http://rsb.info.nih.gov/ij/) by observers (JWN, PS, OWH) blinded to
TMA identity and antibody labeling; data were exported to Excel
(Microsoft Ofﬁce 2010). Total number of neurons was quantiﬁed
from the LFB stained slides, identiﬁed by the presence of an apical
dendrite, nucleus and nucleolus. For analysis, each core was classi-
ﬁed, the cells counted and considered individually. The median num-
ber of immunolabeled cells per tissue core (0.28 mm2) for each C
protein or cell phenotype marker was calculated and statistical analy-
sis carried out using R v3 0.2 software (https://www.R-project.org/).
Statistical analysis
Comparisons in NAWM versus WML and NAGM versus GML of
the total number of immunolabeled cells for each antibody-stained
core was performed using Mann–Whitney U tests and signiﬁcance
taken if P< 0.05. For each tissue of interest, numbers of immunola-
beled cells were counted for individual tissue cores; three separate
cores were obtained from each lesion or normal tissue sample.
In order to examine the relationship between individual pairs of
anti-C antibodies, the number of cells staining positively for each
antibody was used as a continuous variable. Pearson correlation
was used to examine the relationship between pairs of anti-C anti-
bodies. All statistical analysis was performed using R v3 0.2 soft-
ware (https://www.R-project.org/).
RESULTS
Anti-fibrinogen staining kidney and brain
tissues
Kidney sections stained with anti-ﬁbrinogen antibody (see Table 3
for details) demonstrated positive immunostaining. In brain, corti-
cal anti-ﬁbrinogen antibody staining was localized to blood vessel
walls but was absent in nearby neurons and surrounding neuropil,
indicating a lack of blood-brain barrier disruption (Supporting
Information Figure S1); this interpretation was in accord with the
ﬁndings of van Horssen et al (35). Similar results were obtained
using anti-IgG on control brain tissues showing no evidence for
staining of neurons or glia in accord with published results (16) and
supporting the lack of anti-ﬁbrinogen staining interpretation as
demonstrating an intact blood brain barrier.
Control non-inflamed brain tissue
Formalin ﬁxed sections from three cases of non-inﬂamed cortex
(C038, CO40, CO41, Table 2) were stained with the same anti-C
antibodies as used for the TMA sections (Supporting Information
Figure S1). In all cases there was minimal positive immunostaining
of neurons and glia replicating our previous results for non-inﬂamed
cortex (16). There were signiﬁcantly lower numbers of immuno-
stained neurons and glia in control non-inﬂamed tissue as compared
with NAWM and NAGM in MS tissue (16). The non-inﬂamed tis-
sues in this study were from the same cohort as the previous study.
Neurons and glia from cases of other neuroinﬂammatory dis-
eases were often positively stained with anti-C antibodies; exam-
ples of typical staining patterns are shown in the supplemental data
(Supporting Information Figures S2 and S3).
Astrocytic and microglia activation correlate
with elevated numbers of C5aR-positive cells
We compared cores taken from NAGM, GML, NAWM and WML
(Figures 1 and 2) areas in TMA preparations to better understand
the role of complement activation in demyelinating lesions. Astro-
cytes (GFAP1) were found in higher numbers in WML
(P< 0.0001) in comparison to NAWM (Figure 2A). There was a
signiﬁcant increase of GFAP1 cells in GML, (P< 0.0001), com-
pared with NAGM. GFAP1 astrocytes represented only approxi-
mately 10% of total glia in lesion tissue. There was no difference in
the number of Iba-1 immunolabeled microglia in either WML or
GML compared with NAWM or NAGM, respectively; however,
HLA-DR1 activated microglia were increased in WML
(P< 0.0001), as compared with NAWM, and in GML compared
with NAGM (P< 0.0001). In all tissue types, microglia represented
the most frequent immunolabeled cell type (Figure 2A).
Anti-C5aR antibody positively immunostained microglia and a
small number of cells with an astrocytic morphology; neurons were
negative for C5aR as previously reported (22). C5aR positive cells
were increased in WML in comparison to matched NAWM
(P< 0.003, Figure 2B).
Immunolabeling for C component proteins and
regulators in lesion versus non-lesion tissue
Total number of C1q immunolabeled cells was increased in WML
and GML tissue compared with NAWM (P< 3 3 1028) and
NAGM (P< 0.007), respectively (Figure 3A). Total number of
C3b immunopositive cells per core was also increased in WML
and GML tissue compared with NAWM (P< 0.0009) and NAGM
(P< 0.03), respectively (Figure 3B).
We performed ISH for C1QA and C3 mRNA to test whether cort-
ical neurons are a source of complement in the MS brain (Figure 3).
Transcripts of C1QA and C3 were detected in the soma of numerous
cortical neurons that were immunostained for the pan-neuronal pro-
tein HuC/D. Sections incubated in the absence of probe (not shown),
or with scrambled or sense probe, were negative (Figure 3).
C1INH-positive glia were increased in WML compared with
NAWM (P5 2.7 3 1025; Figure 4A). CR1-positive immunola-
beled cells were increased in WML tissue compared with NAWM
(P< 0.001) (Figure 4B). FH-immunolabeled glial cells were
increased in WML in comparison to NAWM, detected using poly-
clonal (P< 0.005) and monoclonal antibodies against distinct FH
regions (Ox-24 vs. FH N-terminus; MBI-15 vs. SCRs 11–15; both
P< 0.01) (Figure 4C,E,F). MBI-15 stains only FH (not FHL or
FHRs); staining with polyclonal anti-FH and MBI-15 were highly
correlated in all TMA cores (R25 0.69) and for neuronal staining
(R25 0.83; data not shown). Immunolabeling with MBC-125, spe-
ciﬁc for FH-related (FHR) proteins 1, 2 and 5 (present as hetero-
oligomers in vivo), demonstrated increased immunopositive glia in
WML compared with NAWM (P< 0.002) (Figure 4G). The num-
ber of clusterin-positive cells was also signiﬁcantly increased in
WML cores (Figure 4D)
In contrast to ﬁndings in WM, we did not observe any difference
between the number of GML and NAGM C1INH, CR1, FH (using
polyclonal FH and mAbs Ox-24 and MBI-15) or FHR (MBC-125
antibody) immuno-positive cells (Figure 5); however, clusterin-
Loveless et al Tissue microarray methodology
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positive cells were increased in GML cores in comparison to
NAGM (P< 0.05, Figure 5D).
Complement immunolabeling of neurons
We investigated whether neurons and non-neuronal cells (glial;
microglia and astrocytes) stained for C components and regula-
tors, and whether the speciﬁc C staining differed between
NAGM and GML. Positively stained neurons and non-neuronal
cells were identiﬁed and quantiﬁed for each of our panel of
antibodies (Tables 4 and 5). Overall, total number of neurons did
not differ between NAGM and GML cores (data not shown).
C1q-positive and C3b-positive non-neuronal cells were increased
in GML compared with NAGM (P< 0.0001 and P< 0.0002,
respectively) with an accompanying increase in the number of
cells positive for regulators and inhibitors (CR1, FH, FHR and
clusterin [all P< 0.05, Table 4]). However, in contrast, signiﬁ-
cantly fewer neurons in GML were immuno-stained for C regula-
tors C1INH, CR1, FH (Ox-24) and FHR proteins compared with
neurons in NAGM (all P< 0.05); the number of neurons
Figure 2. Microglial activation and complement anaphylatoxin
receptor expression in MS lesions. Panel A shows a stacked bar chart
illustrating the constituent cell types in each of our ROIs. Cells
morphologically resembling microglia, astrocytes and neurons were
quantified. There was a significant increase in the numbers of GFAP
positive astrocytes and HLA positive microglia/ macrophages in WML
compared with NAWM, and in GML compared with NAGM
(*P< 0.05). Overall there was no significant difference in the total
number of Iba-1 positive microglia in any tissue type or of gray matter
neurons whether in lesion or non-lesion. Panel B; C5aR immunostain-
ing identified cells with microglial/macrophage morphology. There was
a significant increase in C5aR stained cells in WML as compared with
NAWM (P5 0.00295). IHC shows C5aRpositive staining in NAWM,
WML, GML and NAGM (clockwise from top left) of TMA cases
MS272 and MS273. Median, IQR and full range of data shown. Scale
bars are shown. Abbreviations: NAGM; normal appearing gray matter,
GML; gray matter lesion, WM; white matter, WML; white matter
lesion, C5aR; C5a receptor.
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expressing clusterin was similar in GML and NAGM. These data
suggest a degree of C dysregulation in GML neurons. In support
of this, there was a marked increase in the number of C1q-
positive neurons in GML compared with NAGM (P5 0.0003),
but no difference in C3b-positive neurons (Table 5).
Testing the relationship between individual C
component staining in MS WM and GM
Correlation of C protein staining (on microglia, astrocytes, neurons)
was tested for (i) all cores (Table 6), (ii) white matter cores only
Figure 3. Complement Component
Expression in MS tissue. We quantified the
number of (A) C1q and (B) C3b
immunostained cells of all types in normal
and lesion cores. Panel A; box plots
revealed a significant increase in C1q
positive cells in WML tissue and in GML
tissue compared with normal appearing
WM and GM, respectively. C1q IHC shows
immuno-positive cells with astrocytic
morphology in WML of case MS225,
neuronal morphology in GML from case
MS272 and an absence of staining in
NAWM (case MS203) and NAGM (case
MS230). Inset: In situ hybridization shows
neurons (arrow; brown DAB reaction
product) positive for complement C1QA
mRNA (a), while the scrambled probe (ISH)
is negative (b). All neurons are identified by
expression of HuC/D protein by
immunohistochemistry (blue reaction
product). Panel B; Quantification of C3b
positive cells. There was a significant
increase in the number of C3b positive cells
in WML tissue and in GML tissue compared
with normal appearing WM and GM,
respectively. IHC shows glial C3b staining
from WML of case MS225 (arrows mark
positive glia), neuronal and glial staining
from GML and GM of case MS272 (inset
shows magnified neuron indicating
cytoplasmic and surface staining patterns).
A decrease in cellular staining is shown in
WM from case MS230. Inset: In situ
hybridization shows neurons (arrow, brown
DAB reaction product) express the mRNA
transcript for complement C3 (a) while the
ISH sense probe for C3 is negative (b). All
neurons are identified by expression of
HuC/D protein by immunohistochemistry
(blue reaction product). Median, IQR and full
range of data shown. Abbreviations: NAGM;
normal appearing gray matter, NAWM;
normal appearing white matter, WM; white
matter, GM; gray matter.
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(NAWM, WML; edge and center) (Table 7) and (iii) gray matter
cores only (NAGM, GML; edge and center) (Table 8). Across all
cores, some C components were highly correlated with relevant
regulators, while others were not. Total C1q immunopositive cells
positively correlated with C3b immuno-stained cells (Pearson’s
R25 0.70, P< 0.0001) for all TMA cores, demonstrating that C1q
binding is closely associated with C3b deposition in progressive
MS (Table 6). C1q signal also correlated with C1INH (R25 0.48,
Tissue microarray methodology Loveless et al
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P< 0.0001) and clusterin (R25 0.58, P< 0.0001) signals, provid-
ing evidence of a link between C activation and regulation in the
tissues (Table 6). Separate analysis in GM and WM cores showed a
positive correlation between all components and regulators in WM
(all P< 0.05, Table 7); however, in GM many components and
regulators showed no correlation, suggesting C dysregulation
within cortical GM (Table 8).
Classification tree analysis identifies C1q1 cell
number as a predictor of the lesion state
To investigate whether individual or sets of C components strongly
predict WML or GML, classiﬁcation tree analysis was performed
using the rpart library in R (https://cran.r-project.org/web/packages/
rpart/index.html); this tool partitions data to determine tissue classi-
ﬁcation. Here all cell types were analyzed; neurons and glia. For
GM cores, C1q staining stood out as a lesion discriminator; the cut-
off for C1q determined by the model was 8.5: if total C1q positive
cells was >8.5/core this signiﬁed a lesion, and <8.5 signiﬁed nor-
mal GM. Likewise, the cutoff determined by the model for WM
was 13.5. 69% (18/26) of GML tissue cores had >8.5 C1q-positive
cells compared with 10% (3/30) of NAGM cores and 88% (54/61)
of WML tissue cores had >13.5 C1q-positive cells compared with
2.3% (1/43) of NAWM cores. Although some other C proteins
were also predictive, adding in other variables did not improve the
capacity of the model to successfully classify cores as either lesion
or non-lesion, demonstrating that number of C1q1 cells best dis-
criminates cortical GM and WMMS lesion from normal tissue.
DISCUSSION
TMA methodology is ideally suited for analyzing tissue marker
expression, revealing interactions between large numbers of func-
tionally related proteins and identifying proteins or protein sets that
correlate with tissue pathology. Our systematic quantitative analy-
sis revealed that increased immunostaining for C proteins is a ubiq-
uitous feature of WM and GM lesions in progressive MS.
Furthermore, the ﬁndings suggest that C is dysregulated in GM
lesions, leaving cortical GM neurons at risk of C-mediated damage
because of the presence of C1q, in the absence of key complement
regulatory proteins. Indeed, statistical analysis has identiﬁed total
(neurons and glia) C1q-positive cell number as an independent pre-
dictor of lesion presence in GM and WM, suggesting its use as a
potential biomarker.
Complement activation immunolabels cells in
progressive MS lesions
Anti-C1q and C3b (iC3b/C3b) positively stained microglia/macro-
phages (HLA-DR1) of WML and neurons and microglia (HLA-
DR1) of GML (Tables 1 and 2 and Figure 2). The number of anti-
C3b and -C1q immunolabeled cells were strongly correlated (Pear-
son coefﬁcient R25 0.70, P< 0.0001), providing further evidence
for C activation via the classical pathway on glia and neurons in
MS plaques (5, 16, 21). We have previously demonstrated using
double immunolabeling that C1q and iC3b/C3b co-localized on
reactive astrocytes, microglia and neurons in MS (16), and in situ
hybridization by ourselves and others showed expression of both
C3 and C1qA mRNA in neurons and microglia in MS and other
neurodegenerative diseases (23, 28, 32, 37). C activation is a poten-
tial stimulus for microglial activation and expression of reactive
oxygen species and pro-inﬂammatory cytokines, which are associ-
ated with neuronal damage and demyelination (1, 6). Given the
paucity of T and B cell lymphocytes in progressive MS lesions (2,
26), C activation likely represents an important contributor to MS
pathology.
Although the above data support local C activation in lesions,
immunolabeling cannot readily discriminate whether staining
represents protein deposited on the cell surface as a result of
activation or within the cell cytoplasm as a consequence of bio-
synthesis. We performed ISH to show C1QA and C3 mRNA is
expressed in cortical neurons co-labeled with the neuron speciﬁc
marker HuC/D (Figure 3). C1QA and C3 mRNA have been con-
sistently demonstrated in MS sections (23, 37) and in glia from
Huntington’s disease brain tissue (32). Furthermore anti-
ﬁbrinogen staining of neurons in MS brain was negative sup-
porting the argument that systemic C does not diffuse across the
blood–brain barrier in this disease. These data are consistent
with the interpretation that the blood–brain barrier is grossly
intact in MS (9, 16), and that neuronal and glial C staining in
MS represents local C biosynthesis (28).
Complement regulation in progressive MS
The increased number of C1q immunolabeled cells in WML is
associated with increased C1INH staining on the same cells, sup-
porting on-going activation and regulation of the classical pathway
in WML. Several other C regulators were also increased in WML
compared with NAWM; FH, the main regulator of the alternative
pathway (38), CR1, a membrane bound activation pathway
Figure 4. Complement regulator expression in MS white matter. Each
of panels A–G: Box plots show total immunostained cell counts and
examples of typical staining in WML (top) and NAWM (bottom) of C
pathway regulators; C1INH, CR1, FH (as stained with polyclonal anti-FH
antibody, and mAb Ox-24 and MBI-15), the terminal complex regulator,
clusterin and FH-Related protein (FHR). All regulators are shown to be
increased in WML compared with NAWM (all P< 0.05). Panel A: WML
and NAWM IHC from case MS230, inset shows C1INH astrocytic stain-
ing from case MS203. Panel B: CR1 positive glia in WML of case
MS273 and reduced staining in NAWM of case MS230. Panel C: Posi-
tive FH glial staining in an active NAWM peri-plaque region of case
MS197 and lack of cellular staining in NAWM of case MS106. Panel D:
Terminal pathway regulator, clusterin positive glia of case MS197 WML
edge and reduced in NAWM of case MS230. Monoclonal antibodies Ox-
24 and MBI-15 both recognize epitopes on FH (N-terminal and mid-
section, respectively), MBC-125 is specific for FHR proteins 1/2/5. Panel
E: Ox-24 positive glia from WML and NAWM of case MS377. Panel F:
ramified MBI-15 glia of WML center from case MS377 and reduced
staining in NAWM of case MS273. Panel G: FHR positive active glia
from WML edge of case MS197 and lack of cellular staining in NAWM
of the same case. Median, IQR and full range of data shown. Abbrevia-
tions: NAGM; normal appearing gray matter, NAWM; normal appearing
white matter, C1INH; C1 inhibitor, CR1; complement receptor 1, FH;
Factor H; FHR; Factor H related proteins.
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regulator, and clusterin, a terminal pathway regulator. There was
positive correlation between immunolabeling for C3b and its two
main regulators, FH and CR1. Staining for FH is complicated by
the fact that a battery of homologous FH-related proteins (FHRs)
exist to control FH activity; many FH antibodies cross-react with
FHRs. To resolve this complexity, we used a panel of anti-FH and
anti-FHR antibodies; a polyclonal antibody that detects FH and
FHRs, two anti-FH mAbs, one of which (MBI-15) is FH-speciﬁc,
Tissue microarray methodology Loveless et al
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and a mAb that is speciﬁc for FHRs 1, 2 and 5 (MBC-125). Stain-
ing with these antibodies demonstrated that both FH and FHRs
were present in MS WM lesions, a ﬁnding that is in accord with
the observed co-localization of FH and FHR on kidney and retinal
cells (13). FHRs are antagonists of FH, blocking its ability to bind
C3b and regulate the alternative pathway (10, 11, 13, 15, 31). The
demonstration that both FH and FHRs are present in WM lesions
raises the possibility that C regulation by FH is antagonized by
FHRs in the lesions. In contrast to the ﬁndings in WM, expression
of C regulators in GM lesions was minimal, suggesting that C acti-
vation is poorly controlled in GM.
Complement activation and dysregulation on
neurons contribute to neurodegeneration in
cortical gray matter lesions
Neuronal cytoplasm C expression has been described in cultured
human cells (33) in animal models (5, 28) and in human post
Figure 5. Complement regulator expression in MS gray matter. Each
of panels A–G: Box plots show total immunostained cell counts and
examples of typical staining in GML (top) and NAGM (bottom) of C
pathway regulators; C1INH, CR1, FH (as stained with polyclonal anti-
FH antibody, and mAb Ox-24 and MBI-15), the terminal complex regu-
lator, clusterin and FH-Related protein (FHR). In contrast to white mat-
ter, our analysis revealed the total number of complement regulator
positive cells to be unchanged between normal and lesioned GM with
the exception of clusterin. Panel A; C1INH positive neurons and glia in
GML and NAGM of case MS249. Panel B: CR1 positive GML cells of
case MS273 and NAGM of case MS377. Panel C: Polyclonal anti-FH
staining of neuritic-like processes (black arrow) and granular areas
within neurons (blue arrows) in NAGM of case MS160 and GML of
case MS225. Panel D: neuronal clusterin staining in GML of case
MS272 and NAWM of case MS249. Panel E: Ox-24 (anti-FH) posi-
tively stained neurons (blue arrow) and glia (black arrow) from GML
and NAGM of case MS255. Panel F: MBI-15 (anti-FH specific) posi-
tively stained GML and NAGM neurons (blue arrows) of cases MS377
and MS234, respectively. Panel G: FHR positive staining in GML and
NAGM of case MS225. Median, IQR and full range of data shown.
Abbreviations: NAGM; normal appearing gray matter, NAWM; normal
appearing white matter, C1INH; C1 inhibitor, CR1; complement recep-
tor 1, FH; Factor H; FHR; Factor H related proteins.
Table 4. Non-neuronal cell counts in normal-appearing gray matter (NAGM) and gray matter lesions (GML).
Target Non-neuronal cell counts
NAGM GML Mann–Whitney U test
Median IQR Median IQR P value
C1q 0.0 0.00–1.00 9.0 4.00–19.50 <0.0001
C3b 1.0 0.00–6.00 10.0 2.75–24.75 0.00015
C1INH 12.5 10.00–17.00 14.0 4.00–20.00 0.82
CR1 9.0 6.00–15.00 17.0 10.00–28.00 0.0007
FH 10.0 5.00–13.00 17.5 9.00–51.00 0.004
Clusterin 11.5 8.00–18.00 19.0 11.25–40.00 0.002
Ox-24 10.0 6.00–11.00 15.5 10.00–23.00 <0.0001
MBI-15 10.0 1.50–22.00 21.5 8.75–38.25 0.007
MBC-125 6.0 4.75–23.25 34.0 15.00–48.00 0.001
Table 5. Neuronal cell counts in normal-appearing gray matter (NAGM) and gray matter lesions (GML).
Target Neuronal cell counts
NAGM GML Mann–Whitney U test
Median IQR Median IQR P value
C1q 0.0 0.00–2.00 4.0 0.00–6.00 0.0003
C3b 1.0 0.00–9.00 3.5 2.00–8.75 0.18
C1INH 24.0 18.00–28.00 16.0 12.00–20.00 0.0003
CR1 39.0 28.00–45.00 25.0 18.50–35.00 0.002
FH 27.0 19.00–35.00 26.0 11.70–30.00 0.37
Clusterin 44.5 33.75–63.00 42.5 33.30–53.50 0.51
Ox-24 32.5 28.50–36.00 21.0 19.00–24.75 <0.0001
MBI-15 24.0 13.00–30.00 20.0 10.00–28.75 0.21
MBC-125 41.5 27.80–51.00 29.0 17.00–34.00 0.005
Mann–Whitney U test was used to compare complement proteins and regulator expression on both non-neuronal (glial) cells and on neuronal
cells of NAGM and GML. Positive cells were counted per tissue array core (0.28 mm2 area) and defined as either non-neuronal (Table 4) or neuro-
nal (Table 5). Median, interquartile range (IQR) and P values are shown. Significance taken at P< 0.05 and shown in BOLD.
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mortem brain (16, 23, 37). The ISH images shown here demonstrate
C1QA and C3 mRNA expression in neuronal cytoplasm and nuclei,
supporting previously published studies (23, 37). Here we showed
that signiﬁcantly increased numbers of C1q immunolabeled neurons
(representing >10% of the total neurons) were present in GML tis-
sue cores. This ﬁnding agrees with the increased C1q
immunolabeling and C1q mRNA expression described in associa-
tion with degenerating synapses in MS lesions in hippocampus (22,
37). There was also increased C3b staining in GM lesions which,
together with the reduced numbers of neurons immunolabeling with
C regulators in GML compared with GM, provide strong supporting
evidence for C dysregulation and activation on neurons in GML.
Table 6. Total cell counts (all cores).
Component/regulator C1q C3b C1INH Clusterin CR1 FH
C1q n/a – – – – –
C3b R250.70
P<0.0001
n/a – – – –
C1INH R250.48
P<0.0001
R250.39
P<0.0001
n/a – – –
Clusterin R250.58
P<0.0001
R250.50
P<0.0001
R250.47
P<0.0001
n/a – –
CR1 R250.097
P5 0.24
R2520.13
P50.099
R250.31
P<0.0001
R250.34
P<0.0001
n/a –
FH R250.38
P<0.0001
R250.13
P50.12
R250.27
P50.0004
R250.59
P<0.0001
R250.57
P<0.0001
n/a
Table 7. White matter cell counts (NAWM, WML; lesion edge and center).
Component/regulator C1q C3b C1INH Clusterin CR1 FH
C1q n/a – – – – –
C3b R250.65
P<0.0001
n/a – – – –
C1INH R250.63
P<0.0001
R250.59
P<0.0001
n/a – – –
Clusterin R250.63
P<0.0001
R250.61
P<0.0001
R250.58
P<0.0001
n/a – –
CR1 R250.46
P<0.0001
R250.27
P50.01
R250.38
P<0.0001
R250.57
P<0.0001
n/a –
FH R250.47
P<0.0001
R250.30
P50.007
R250.30
P<0.0001
R250.64
P<0.0001
R250.65
P<0.0001
n/a
Table 8. Gray matter cell counts (NAGM, GML; lesion edge and center). Abbreviations: n/a5not applicable, R25 regression coefficient.
Component/regulator C1q C3b C1INH Clusterin CR1 FH
C1q n/a – – – – –
C3b R250.70
P<0.0001
n/a – – – –
C1INH R250.37
P50.0065
R250.41
P50.0009
n/a – – –
Clusterin R25 0.25
P50.08
R250.38
P50.003
R25 0.15
P50.20
n/a – –
CR1 R2520.14
P50.31
R25 0.04
P50.77
R2520.06
P50.62
R250.29
P50.009
n/a –
FH R25 0.17
P50.25
R250.33
P50.01
R25 0.07
P50.60
R250.39
P<0.0007
R250.53
P<0.0001
n/a
Pearson correlation was used to examine the relationships between cells staining positively for each antibody of the Complement Pathways for
all tissues types. Correlations were calculated between total cell counts (Table 6), white matter cell counts (Table 7) and gray matter cell
counts (Table 8).
Significant correlation was P< 0.05 and shown in BOLD.
Tissue microarray methodology Loveless et al
12 Brain Pathology •• (2017) ••–••
VC 2017 International Society of Neuropathology
TMA analysis; an appropriate methodology for
analysis of a complex innate immune pathway
TMA methodology has several advantages over traditional IHC
methods; it requires only small amounts of formalin ﬁxed tissue
and much reduced quantities of reagents, including expensive anti-
bodies, compared with traditional IHC (31). Furthermore, the TMA
approach samples a consistent area of lesion, reduces variability of
experimental conditions and increases reliability of immunostaining
data, making it an ideal technique to validate newly generated anti-
bodies (36); and compare sets of antibodies as used in this study
(10, 11, 31). One possible criticism of this approach when applied
to MS tissue is the debate regarding heterogeneity of MS plaque
immunopathology (3, 21) such that individual cores will show var-
iations in pathology. To ensure tissue pathology is uniform between
TMA cores we only selected chronic active plaques and ensured
that the severity of inﬂammation and pathology was uniform within
lesion type by controlling for severity of myelin loss, microglial
number and activation status (anti-Iba and anti-HLA-DR) and T
and B cell immunostaining.
CONCLUSION
The C pathways are pivotal for the CNS innate immune response
(24); previous studies have shown an association between individ-
ual C proteins and MS pathology (5, 16, 21, 37); here, using TMA
methodology in MS tissue in conjunction with control tissues and
statistical analyses, we have demonstrated a role for C in progres-
sive MS in both WM and GM lesions and demonstrated an associa-
tion between functionally related C proteins and tissue pathology.
Statistical modeling revealed that the number of C1q-positive cells
in WM or GM was highly predictive of a lesion. In GM lesions,
the data suggest that C activation is associated with dysregulation;
a ﬁnding present in other neuroinﬂammatory diseases such as reti-
nal inﬂammation in Age Related Macular Degeneration (AMD)
(20, 34). AMD is associated with a Tyr402His amino acid substitu-
tion in FH and dysregulation and uncontrolled activation of C in
the retina. The retinal pathology typically includes deposits of C3,
C3d, iC3b, terminal pathway components, clusterin and FHRs
(38). In our study, evidence for C dysregulation in GML is pro-
vided by an increase of C1q-positive neurons with reduced
immuno-labeling for the regulators FH, FHR 1/2/5 and C1INH
compared with NAGM.
With regard to clinical relevance, measurement of C proteins in
serum and CSF is now validated as a biomarker of tissue inﬂamma-
tion in MS (15). Here we show that tissue-associated C proteins
also mark disease in progressive MS and may guide future thera-
peutic approaches targeting the classical pathway.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Figure S1. Control Immunohistochemistry examples; non-
inﬂammatory control tissue and anti-ﬁbrinogen and IgG1 isotype
controls. Panel A: Tissue sections from non-inﬂammatory con-
trol cases (CO38, 0040, 0041) showing examples of comple-
ment staining in NAWM and NAGM. Panel B: lack of cellular
ﬁbrinogen staining in NAWM of TMA case MS2SS. Panel C:
ﬁbrinogen positive blood vessel wall surrounded by immuno-
negative neurons of NAGM of TMA case MS234. Panels D
and E: ﬁbrinogen staining in human kidney as a positive con-
trol. Panel F: IgG control staining. Panel G: no primary anti-
body negative control.
Figure S2. Control Immunohistochemistry examples. Tissue
sections from Herpes simplex encephalitis [HSV (cases B5125-9
and B5046-15)] immunostained for C proteins investigated in
this study; (A) polyclonal antibody to Clq immunolabels several
neurons within GM; (B) C3b1 glia (arrows) within the WM of
temporal lobe; (C) C3b1 degenerating neurons within the tem-
poral cortex; (D) C1INH1 neurons; (E) clusterin1 immunola-
beled axons (arrow) and glia within WM of temporal lobe; (F)
clusterin1 neurons and occasional glia within GM; (G)
C5aR1 cells with a microglia/macrophage morphology in a
perivascular distribution; (H) Ramiﬁed C5aR1 glia in WML
edge. All images 403 magniﬁcation.
Figure S3. Control Immunohistochemistry examples. Sec-
tions from parafﬁn wax embedded formalin ﬁxed Alzheimer’s
disease cerebral cortex immunostained for C proteins; (A) Clq
antibody showing positive immunolabeling of pyramidal neu-
rons (A303/09); (B) C3b immunolabeling neurons and amyloid
plaques, and occasional glia (A307/07); (C) C1INH labeled glia
(A173/05); (D) polyclonal anti-FH staining with characteristic
granular immunolabeling within the neuronal cytoplasm (A173/
05); (E) MBC-125 (FHR protein) immunolabeling of neuronal
cytoplasm (A192/07); (F) Ox-24 antibody demonstrating a simi-
lar pattern of immunolabeling of neurons as seen with the poly-
clonal anti-FH anti-sera (A307/07); (G) MBI-15 (FH-speciﬁc)
antibody immunolabeling of neuronal cytoplasm (A307/05); (H)
Anti-clusterin stained neurons from case A303; (I) CR1 positive
neurons from GM of case A307.
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